HANAC Syndrome

What's on this Page

HANAC Syndrome: A Comprehensive Medical Review

Introduction

Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps (HANAC) syndrome is an extremely rare autosomal dominant multisystem disorder first comprehensively characterized by Plaisier and colleagues in 2007. According to trusted medical organizations including the National Institutes of Health (NIH), Orphanet, and the National Organization for Rare Disorders (NORD), this condition represents a distinct phenotype within the spectrum of COL4A1-related disorders, characterized by a unique combination of cerebrovascular disease, kidney abnormalities, muscle cramps, and ocular manifestations. The syndrome derives its name from its four cardinal features: Hereditary Angiopathy, Nephropathy, Aneurysms, and muscle Cramps.^[1]^[2]^[3]^[4]

Definition and Classification

Disease Definition

According to Orphanet, the European reference portal for rare diseases, HANAC syndrome is defined as “a rare multisystemic disease characterized by small-vessel brain disease, cerebral aneurysm, and extracerebral findings involving the kidney, muscle, and small vessels of the eye”. The condition is classified under multiple medical taxonomies:^[3]

OMIM Classification: Various entries under COL4A1-related disorders
Orphanet Code: ORPHA:73229
MedGen ID: C1867801

Synonyms and Nomenclature

The condition is known by several names in medical literature:^[5]^[3]

HANAC syndrome
Hereditary angiopathy with nephropathy, aneurysms, and muscle cramps syndrome
Autosomal dominant familial hematuria-retinal arteriolar tortuosity-contractures syndrome
Hereditary angiopathy-nephropathy-aneurysms-muscle cramps syndrome

Epidemiology and Demographics

Prevalence and Geographic Distribution

HANAC syndrome is considered one of the rarest genetic conditions worldwide:

Global Prevalence: According to multiple trusted sources, the prevalence is estimated at less than 1 per 1,000,000 individuals.^[2]^[6]^[3]

Documented Families: Only six to seven affected families have been described in the scientific literature since the syndrome’s initial characterization.^[6]^[2]^[3]

Geographic Distribution: Cases have been reported primarily in:

France (original three families described by Plaisier et al.)
Japan (recent case series)
Other isolated reports worldwide

Demographic Characteristics

Age at Onset: Clinical manifestations typically begin in early childhood, with muscle cramps often being the first symptom.^[7]^[3]^[5]

Gender Distribution: The condition affects both males and females equally, consistent with its autosomal dominant inheritance pattern.^[4]^[3]

Family History: Given the autosomal dominant inheritance, affected individuals typically have one affected parent, though up to 27% of COL4A1 mutations may be sporadic.^[1]

Pathophysiology and Molecular Mechanisms

Genetic Basis

COL4A1 Gene Mutations: HANAC syndrome is caused by heterozygous mutations in the COL4A1 gene located on chromosome 13q34. This gene encodes the α1 chain of type IV collagen, a crucial component of basement membranes throughout the body.^[8]^[2]^[3]

Specific Mutation Localization: Unlike other COL4A1-related disorders, all mutations causing HANAC syndrome are specifically localized within exons 24 and 25, corresponding to the CB3[IV] domain of the protein. This domain encompasses major integrin-binding sites critical for cell-basement membrane interactions.^[9]^[10]^[3]

Known Mutations: To date, six pathogenic variants have been identified, all affecting glycine residues within a 30-amino acid region of the protein. Recent reports have identified novel mutations including:^[10]^[3]

c.1538G>A (p.Gly513Asp) in a Japanese family ^[7]
Multiple glycine substitutions in the CB3[IV] domain ^[10]

Molecular Mechanisms

Type IV Collagen Structure: Type IV collagen is composed of three α chains (α1α1α2) that form a triple helix structure. The COL4A1 gene encodes the α1 chain, which combines with another α1 chain and an α2 chain to form the complete collagen IV molecule.^[2]^[1]

Basement Membrane Function: Type IV collagen networks are fundamental components of basement membranes, which are thin sheet-like structures that separate and support cells in virtually all tissues. These membranes are particularly important in blood vessels, kidneys, eyes, and brain tissue.^[11]^[2]

Pathogenic Mechanism: Mutations in the CB3[IV] domain specifically disrupt:^[9]^[1]

Integrin binding: Impaired cell-matrix interactions
Protein folding: Altered triple helix stability
Network formation: Defective basement membrane assembly
Tissue integrity: Weakened support structures throughout the body

Developmental Impact

Embryonic Development: The CB3[IV] domain plays crucial roles during embryogenesis:^[8]

Glomerulogenesis: Proper kidney development and podocyte differentiation
Vascular development: Formation of stable blood vessel walls
Neural development: Brain tissue organization and white matter formation

Clinical Manifestations

Cardinal Features

The syndrome’s name reflects its four primary manifestations, each representing a distinct aspect of the systemic disease:^[12]^[3]^[1]

1. Hereditary Angiopathy (Cerebrovascular Disease)

Small Vessel Disease:^[13]^[14]^[12]

Leukoencephalopathy: Affects periventricular, subcortical, and pontine white matter
Dilated perivascular spaces: Enlarged Virchow-Robin spaces
Microhemorrhages: Small bleeding spots in brain tissue
Lacunar infarcts: Small stroke-like lesions
Generally asymptomatic: Most patients have no neurological symptoms

Large Vessel Disease:^[14]

Intracranial aneurysms: Predominantly affect the carotid siphon
Typically small: Usually do not rupture
Multiple aneurysms: May occur in some patients
Lower hemorrhage risk: Compared to other COL4A1 disorders

2. Nephropathy (Kidney Disease)

Renal Manifestations:^[3]^[5]^[8]

Hematuria: Blood in urine, often microscopic
Bilateral renal cysts: Both cortical and medullary cysts
Chronic kidney disease: Progressive decline in kidney function
Glomerular abnormalities: Including glomerular cysts
Proteinuria: Protein in urine (variable)

Pathological Changes:^[8]

Delayed glomerulogenesis: Abnormal kidney development
Podocyte dysfunction: Impaired filtering cells
Basement membrane abnormalities: Structural defects in kidney filters
Inflammatory infiltrates: Around blood vessels and glomeruli

3. Aneurysms (Vascular Abnormalities)

Intracranial Aneurysms:^[12]^[14]^[3]

Location: Primarily on carotid siphon
Characteristics: Usually small and stable
Multiple occurrence: May be present in several locations
Low rupture risk: Unlike typical cerebral aneurysms
Monitoring required: Regular imaging surveillance needed

4. Muscle Cramps

Clinical Characteristics:^[15]^[5]^[7]

Early onset: Begin in early childhood
Spontaneous occurrence: Without obvious triggers
Any muscle affected: Not limited to calf muscles
Unique features: Severe pain without visible muscle contraction
Duration: Several minutes with residual discomfort lasting 24-48 hours
Elevated CK: Persistently elevated creatine kinase levels

Associated Clinical Features

Ocular Manifestations

Retinal Abnormalities:^[16]^[1]^[3]

Bilateral retinal arteriolar tortuosity: Present in 100% of patients
Retinal hemorrhages: Due to vessel fragility
Transient vision loss: Following minor trauma
Cataracts: May occur in some patients
Axenfeld-Rieger anomaly: Anterior segment developmental anomalies

Cardiovascular Features

Cardiac Manifestations:^[1]^[3]

Supraventricular arrhythmias: Abnormal heart rhythms
Palpitations: Awareness of heartbeat
Tachycardia: Rapid heart rate episodes

Other Systemic Features

Additional Manifestations:^[2]^[3]^[1]

Raynaud phenomenon: Temporary restriction of blood flow to fingers/toes
Headaches: Variable frequency and severity
Normal intellectual development: Cognitive function typically unaffected

Diagnostic Approach

Clinical Diagnosis

The diagnosis of HANAC syndrome is established through recognition of the characteristic clinical constellation and genetic confirmation:^[9]^[3]^[1]

Diagnostic Criteria (Proposed):

Bilateral retinal arteriolar tortuosity (pathognomonic)
Muscle cramps beginning in childhood
Evidence of nephropathy (hematuria, cysts)
Small vessel brain disease on MRI
Family history consistent with autosomal dominant inheritance

Laboratory Investigations

Biochemical Assessment

Muscle-Related Tests:^[15]^[5]^[7]

Creatine kinase (CK): Persistently elevated levels
Electromyography (EMG): Usually normal findings
Muscle biopsy: Not typically required

Renal Function:^[3]^[8]

Urinalysis: Microscopic hematuria, possible proteinuria
Serum creatinine: May be elevated with disease progression
Estimated GFR: Progressive decline over time
24-hour urine collection: Quantification of protein and blood loss

Genetic Testing

Molecular Diagnosis:^[10]^[9]^[3]

COL4A1 gene sequencing: Focus on exons 24 and 25
Targeted testing: CB3[IV] domain analysis
Family studies: Cascade testing of relatives
Genetic counseling: Essential for family planning

Imaging Studies

Neuroimaging

Magnetic Resonance Imaging (MRI):^[13]^[14]^[12]

T2/FLAIR sequences: Bilateral, symmetric white matter hyperintensities
Location: Periventricular, subcortical, and pontine regions
Pattern: Confluent changes with U-fiber sparing
Additional findings: Dilated perivascular spaces, microhemorrhages

Magnetic Resonance Angiography (MRA):^[14]

Intracranial aneurysms: Predominantly on carotid siphon
Small size: Usually <7mm diameter
Stability: Generally stable over time
Multiple aneurysms: May occur

Computed Tomography (CT):^[12]

Limited utility: Shows white matter hypodensities
Calcifications: Not typically present
Emergency use: For acute symptoms

Renal Imaging

Ultrasound:^[3]

Bilateral renal cysts: Both cortical and medullary
Kidney size: Usually normal or slightly enlarged
Echogenicity: May be increased

Advanced Imaging:

CT or MRI: Better characterization of cysts
Contrast studies: Assessment of kidney function

Ophthalmological Assessment

Fundoscopy:^[1]^[3]

Retinal arteriolar tortuosity: Bilateral and pathognomonic
Retinal hemorrhages: May be present
Optic disc: Usually normal
Vessel caliber: May be reduced

Advanced Studies:^[1]

Optical Coherence Tomography-Angiography (OCT-A): Shows superficial plexus tortuosity
Fluorescein angiography: When indicated for retinal bleeding

Differential Diagnosis

Primary Considerations

Other COL4A1-Related Disorders

Familial Porencephaly:^[17]^[4]

Brain lesions: Porencephalic cysts and hemorrhages
Severity: More severe neurological symptoms
Age of onset: Often neonatal or early infancy
Muscle cramps: Not a prominent feature
Kidney disease: Less common

Brain Small-Vessel Disease with Hemorrhage:^[4]

Hemorrhagic tendency: Higher risk of brain bleeding
Stroke symptoms: More likely to have clinical strokes
Porencephaly: May develop secondary lesions
Systemic features: Less prominent than HANAC

Other Nephropathy Syndromes

Alport Syndrome:^[3]

Hearing loss: Progressive sensorineural hearing loss
Eye abnormalities: Anterior lenticular cone
Inheritance: X-linked, autosomal recessive, or dominant
Brain disease: Not typically present

Autosomal Dominant Polycystic Kidney Disease (ADPKD):^[18]

Kidney cysts: Larger and more numerous
Liver cysts: Common associated finding
Hypertension: Early and prominent
Brain aneurysms: May occur but different pattern

Secondary Considerations

Ehlers-Danlos Syndromes:^[1]

Joint hypermobility: Prominent feature
Skin involvement: Hyperextensible, fragile skin
Vascular type: May have similar aneurysm risk

CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy):

White matter disease: Similar MRI appearance
Migraine: Prominent symptom
Strokes: More likely to be symptomatic
Family history: NOTCH3 mutations

Treatment and Management

Multidisciplinary Approach

The management of HANAC syndrome requires comprehensive care involving multiple specialists:^[17]^[4]

Symptomatic Management

Neurological Care:

Seizure management: Anticonvulsants when indicated
Stroke prevention: Blood pressure control, lifestyle modification
Headache treatment: Appropriate analgesics
Avoiding anticoagulants: Due to hemorrhage risk

Nephrology Management:^[8]^[3]

Blood pressure control: ACE inhibitors or ARBs preferred
Proteinuria management: Reduction strategies
Chronic kidney disease: Monitoring and supportive care
Dialysis/transplant: For end-stage disease

Ophthalmological Care:^[1]

Regular monitoring: For retinal changes and hemorrhages
Cataract surgery: When visually significant
Low vision aids: If visual impairment develops
Trauma prevention: Eye protection recommendations

Preventive Measures

Lifestyle Modifications:^[4]

Avoid contact sports: High risk of head trauma
Blood pressure management: Maintain optimal levels
Smoking cessation: Reduce vascular risk
Regular exercise: Low-impact activities recommended

Medical Precautions:^[4]

Avoid anticoagulants: Increased bleeding risk
Careful antiplatelet use: Weigh risks and benefits
Pregnancy management: Cesarean delivery recommended
Anesthesia considerations: Awareness of vascular fragility

Surveillance and Monitoring

Regular Assessments

Neurological Monitoring:^[14]^[4]

Annual MRI: Monitor white matter changes
MRA every 2-3 years: Aneurysm surveillance
Blood pressure checks: Regular monitoring
Neurological examination: Detect new symptoms

Renal Monitoring:^[8]^[3]

Annual kidney function: Creatinine, eGFR
Urinalysis: Monitor hematuria and proteinuria
Blood pressure: Regular checks
Renal imaging: Periodic ultrasound

Ophthalmological Surveillance:^[1]

Annual eye exams: Monitor retinal changes
Fundus photography: Document vessel tortuosity
Visual field testing: If symptomatic
OCT-A: When available for vessel assessment

Prognosis and Natural History

Disease Course

Overall Prognosis:^[14]^[3]

Life expectancy: Generally normal with appropriate care
Quality of life: Variable depending on symptom severity
Progressive nature: Some features may worsen over time
Variability: Wide range of severity even within families

Specific Outcomes

Neurological Prognosis:^[14]

Stroke risk: Lower than other COL4A1 disorders
Cognitive function: Usually preserved
Seizures: Uncommon but may develop
Aneurysm rupture: Very rare in HANAC patients

Renal Outcomes:^[8]^[3]

Chronic kidney disease: Progressive in some patients
End-stage disease: May require dialysis or transplant
Hypertension: Common complication
Proteinuria: May develop or worsen over time

Ophthalmological Outcomes:^[1]

Vision preservation: Generally good with monitoring
Retinal hemorrhages: May cause temporary vision loss
Cataracts: May require surgical intervention
Overall visual prognosis: Usually favorable

Prognostic Factors

Favorable Indicators:

Early diagnosis and monitoring
Good blood pressure control
Avoidance of trauma and high-risk activities
Regular medical surveillance

Unfavorable Factors:

Late diagnosis
Poor blood pressure control
Trauma exposure
Non-compliance with monitoring

Genetic Counseling and Family Planning

Inheritance Pattern

Autosomal Dominant:^[2]^[3]

Transmission risk: 50% for each pregnancy
Penetrance: Variable expression within families
Anticipation: Not typically observed
De novo mutations: May occur in up to 27% of cases

Reproductive Counseling

Preconception Counseling:

Risk assessment: 50% transmission probability
Prenatal testing: Available for known mutations
Family planning: Discussion of reproductive options
Genetic counseling: Professional guidance recommended

Pregnancy Management:^[4]

Cesarean delivery: Recommended to reduce trauma risk
Fetal monitoring: Regular assessment
Maternal care: Blood pressure monitoring
Delivery planning: Multidisciplinary team approach

Genetic Testing Considerations

Testing Indications:^[17]^[4]

Characteristic clinical features
Family history of COL4A1 disorders
Unexplained leukoencephalopathy
Combination of kidney, eye, and muscle symptoms

Family Screening:

At-risk relatives: Testing recommended
Asymptomatic carriers: May have subclinical features
Cascade screening: Systematic family evaluation
Counseling support: Essential throughout process

Research and Future Directions

Current Research Areas

Pathophysiology Studies:^[10]^[8]

Animal models: Mouse studies revealing disease mechanisms
Basement membrane biology: Understanding collagen IV function
Cell-matrix interactions: Role of integrin binding
Developmental biology: Embryonic effects of mutations

Clinical Research:

Natural history studies: Long-term outcome assessment
Biomarker development: Disease monitoring tools
Treatment trials: Symptomatic management optimization
Quality of life research: Patient-reported outcomes

Emerging Technologies

Diagnostic Advances:

Advanced imaging: Better characterization of disease features
Biomarker discovery: Non-invasive monitoring tools
Genetic testing: Improved mutation detection methods
Functional assays: Assessment of protein function

Therapeutic Development:

Gene therapy: Potential future treatment
Pharmacological approaches: Targeting disease mechanisms
Regenerative medicine: Tissue repair strategies
Precision medicine: Individualized treatment approaches

Global Health Perspectives

Healthcare Access

Developed Countries:

Specialized centers: Access to multidisciplinary care
Genetic services: Available testing and counseling
Advanced imaging: Comprehensive diagnostic capabilities
Research participation: Opportunities for clinical trials

Resource-Limited Settings:

Diagnostic challenges: Limited genetic testing availability
Basic care: Focus on symptom management
International collaboration: Telemedicine and consultation
Capacity building: Training local healthcare providers

Public Health Implications

Awareness and Education:

Healthcare provider training: Recognition of rare features
Patient advocacy: Support groups and resources
Research funding: Investment in rare disease research
International registries: Global data collection efforts

Conclusion

HANAC syndrome represents a unique and fascinating example of how mutations in a single gene can result in a complex multisystem disorder with distinctive clinical features. As one of the rarest genetic conditions known to medicine, with only six to seven families described worldwide, it challenges our understanding of genotype-phenotype relationships and highlights the importance of precision medicine approaches in rare disease management.

The syndrome’s pathophysiology, rooted in mutations affecting the CB3[IV] domain of type IV collagen, demonstrates the critical importance of cell-matrix interactions in maintaining tissue integrity throughout the body. The specific localization of all known HANAC mutations within exons 24 and 25 of COL4A1 provides compelling evidence for the unique functional significance of this protein domain and its role in integrin binding and basement membrane stability.

From a clinical perspective, HANAC syndrome showcases the importance of recognizing distinctive phenotypic patterns that can distinguish between related genetic conditions. The pathognomonic presence of bilateral retinal arteriolar tortuosity in 100% of patients, combined with the characteristic muscle cramps beginning in early childhood, provides a unique diagnostic signature that sets this condition apart from other COL4A1-related disorders.

The relatively benign neurological course of HANAC syndrome, with typically asymptomatic brain small-vessel disease and low aneurysm rupture risk, contrasts sharply with the more severe manifestations seen in familial porencephaly and other COL4A1 disorders. This phenotypic variability within the spectrum of COL4A1-related conditions emphasizes the importance of mutation-specific effects and provides valuable insights into structure-function relationships in type IV collagen.

The progressive nature of the kidney disease in HANAC syndrome, with the potential for chronic kidney disease and eventual need for renal replacement therapy, underscores the importance of long-term nephrological monitoring and management. The unique glomerular abnormalities observed in mouse models, including delayed podocyte differentiation and glomerular cyst formation, provide important insights into the developmental role of type IV collagen in kidney formation and function.

Current management approaches, while primarily symptomatic and supportive, can significantly improve quality of life and prevent complications when implemented appropriately. The multidisciplinary care model, involving neurologists, nephrologists, ophthalmologists, and genetic counselors, represents the gold standard for rare disease management and ensures comprehensive attention to all aspects of this complex condition.

The genetic counseling implications of HANAC syndrome are particularly important given its autosomal dominant inheritance pattern and the 50% recurrence risk for each pregnancy. The availability of genetic testing for known mutations enables informed family planning decisions and allows for appropriate prenatal counseling when desired.

Looking toward the future, several research directions hold promise for advancing our understanding and treatment of HANAC syndrome. Animal models, particularly the Col4a1 G498V mouse model, continue to provide valuable insights into disease mechanisms and may serve as platforms for therapeutic testing. The development of biomarkers for disease monitoring and progression assessment could significantly improve clinical management.

Emerging therapeutic approaches, including gene therapy and targeted pharmacological interventions, may eventually offer disease-modifying treatments rather than purely symptomatic management. The well-characterized molecular basis of HANAC syndrome makes it an attractive target for precision medicine approaches, though the rarity of the condition presents challenges for clinical trial design and implementation.

The international collaboration required to study such rare conditions highlights the importance of global research networks and patient registries. The sharing of clinical data, tissue samples, and research resources across institutions and countries will be essential for advancing knowledge about HANAC syndrome and developing new treatment approaches.

Healthcare providers should be aware of HANAC syndrome as a potential diagnosis in patients presenting with the characteristic combination of muscle cramps, retinal vessel tortuosity, kidney abnormalities, and brain white matter changes, particularly with a family history suggestive of autosomal dominant inheritance. Early recognition can facilitate appropriate genetic testing, family counseling, and implementation of surveillance strategies to detect and manage complications.

The story of HANAC syndrome also illustrates the power of detailed clinical observation and family-based genetic studies in identifying new disease entities. The careful phenotypic characterization by Plaisier and colleagues, combined with molecular genetic analysis, led to the recognition of this distinct syndrome within the broader spectrum of COL4A1-related disorders.

As our understanding of rare genetic conditions continues to evolve, HANAC syndrome serves as an important model for studying the complex relationships between genetic variation, protein function, and human disease. The insights gained from studying this rare condition contribute not only to improved care for affected individuals but also to broader understanding of basement membrane biology, vascular development, and kidney formation.

The ongoing study of HANAC syndrome will undoubtedly continue to yield valuable insights into type IV collagen biology, basement membrane function, and the mechanisms underlying multisystem genetic disorders. These advances will benefit not only individuals with HANAC syndrome but may also inform our understanding of more common conditions involving basement membrane abnormalities and vascular disease.

HANAC Syndrome

HANAC Syndrome: A Comprehensive Medical Review

References

Related Posts:

Recent Post

features

Categories

Weekly Newsletter